Linifanib (ABT-869)
Linifanib (ABT-869, AL39324, RG3635) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Linifanib (ABT-869) induces autophagy and apoptosis. Phase 3.
| Trivial name | AL39324,RG3635 |
| Catalog Number | S1003 |
| Molecular Formula | C15H9FN2O3 |
| CAS# | 796967-16-3 |
| Inchi | InChI=1S/C15H9FN2O3/c16-12-7-2-1-6-11(12)14-17-13(18-21-14)9-4-3-5-10(8-9)15(19)20/h1-8H,(H,19,20) |
| Inchi Key | OOUGLTULBSNHNF-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F |
| Size | 50mg |
| Supplier Page | http://www.selleckchem.com/products/ABT-869.html |
| Additional Information | https://file.selleck.cn/downloads/struct/Linifanib-ABT-869-chemical-structure-S1003.gif |